A New Bill Would Have Oklahoma Set Prescription Drug Prices. Lawmakers Should Slow Down.
Sen. Jerry Alvord filed Senate Bill 2074 yesterday, and on its face, it reads like a technical fix to pharmacy benefits manager (PBM) contracting law. Don't be fooled by the "certain adjusted reimbursement amount" language in the bill summary. Strip away the procedural framing and SB 2074 is a state-mandated price floor for prescription drug reimbursement, backed by a new compliance and appeals bureaucracy that PBMs — and the health plans and employers who pay them — would have to build and fund.
What the bill as filed actually does
SB 2074 amends 59 O.S. §§ 357 and 360, the statutes governing contracts between PBMs and pharmacy providers. The most consequential provision is a new Section 360(H): it would prohibit a PBM from reimbursing a pharmacy less than the National Average Drug Acquisition Cost (NADAC) for a given prescription, plus a mandatory dispensing fee no lower than Oklahoma's Medicaid fee-for-service rate. Where NADAC isn't available, the floor shifts to wholesale acquisition cost (WAC) — the manufacturer's list price before any negotiated discount, and by design one of the least market-reflective benchmarks in the entire drug pricing system.
Layered on top of that price floor is an expanded appeals regime. The bill would require PBMs to accept supplemental documentation from providers with no cutoff after an appeal is filed, respond to disputed claims within fixed statutory windows (ten days for a decision, thirty for reprocessing), and — if an appeal succeeds — retroactively adjust reimbursement for every claim tied to the same drug across every patient sharing a Bank Identification Number and Processor Control Number, going back to the original date of service. Every adjustment would also need to come with full claim-level reconciliation data attached, or it's automatically "deemed incomplete" under the bill's own text.
Why a price floor is the wrong tool
Pharmacies do have real grievances with PBMs — MAC list opacity, slow-walked appeals, reimbursements that don't track actual acquisition costs. Those are legitimate transparency and process problems, and they deserve a legislative response. But SB 2074 doesn't stop at transparency. It sets the price itself, and NADAC-plus-dispensing-fee is not a neutral number: it's a floor calculated from a national average, applied uniformly to every contracted pharmacy in Oklahoma regardless of the volume discounts, network structures, or negotiated terms that would otherwise let PBMs manage drug spend on behalf of the health plans, employers, and taxpayers who ultimately foot the bill.
That cost doesn't disappear when the state mandates a floor. It gets passed through — to the Oklahoma Health Care Authority for state-covered lives, to self-funded employer plans, and eventually to premiums. Oklahoma wouldn't be the first state to grapple with this; California spent the better part of two legislative sessions negotiating PBM licensure and anti-steering rules before landing on SB 41 last October, and even that bill's own author had two earlier, broader versions vetoed by Governor Newsom over cost and market-structure concerns. Rate-setting-by-statute is a harder problem than it looks on first read, and it's usually better solved through a rulemaking body with the technical capacity to model cost impact — not a floor set in the statute itself before anyone has run the numbers on what it does to Medicaid spending or employer premiums.
What the Legislature should ask before this moves further
Before SB 2074 gets a committee hearing, lawmakers should get an actual fiscal impact estimate from the Oklahoma Health Care Authority on what a NADAC-plus-dispensing-fee floor does to state drug spending, and a comparable estimate of the premium impact on self-funded and fully insured employer plans in the state. They should also ask whether the transparency and appeals-process fixes — which have much broader, less controversial support — can be separated from the price-floor provisions and passed on their own. Community pharmacies deserve a fair, transparent appeals process. Oklahoma taxpayers and employers deserve to know what a mandated reimbursement floor costs before it's signed into law, not after.
